Purchase this article with an account.
E. Reyna–Castelan, J. Jimenez–Sierra, A. Solis–Vivanco, J. Fromow–Guerra, G. Alvarez–Rivera, M. Hernandez–Rojas, R. Bueno–Garcia, O. Ustariz–Gonzalez, V. Alfaro, H. Quiroz–Mercado; OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angiod Streaks Treated With a Single Intravitreal Injection of Bevacizumab . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4283.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the 3–month efficacy of a single dose of IV bevacizumab on the progression SNPDR and PDR by evaluation of ischemic areas and regression of retinal and iris neovascularization
48 patients were enrolled in a prospective, interventional study. Patients were treated with intravitreal bevacizumab 0.1ml (1.25mg). We evaluated visual acuity (VA) leakage capillary closure ischemic areas (CCIA) and macular edema by clinical and fluorescein angiography. A clinical examination was performed at day 0, 1, 30 and 90. Active leakage was measured by fluorescein angiography at 30 and 90 days.
48 patients (32 women, 16 men). 18 SNPDR, 30 PDR. Mean initial visual acuity improved from 20/80 to 20/40 at 3 month evaluation (Friedman Test p= 0.030). CCIA en quadrants improved from 3.33±1.01 to 1.87±0.915 at month 3 (WIlcoxon p=0.003) and macular edema improved from 5.05±3.48 DA to 2.93±2.37 (Wilcoxon p= 0.005). Systemic effects, inflammatory reaction in anterior chamber, endophthalmitis and intraocular hypertension were not observed
These results indicates the trend that intravitreal bevacizumab decrease ischemic areas, iris and retinal neovascularization in a three months follow–up. Intravitreal bevacizumab reduce progression of PDR in a 3 month period. Improve in visual acuity may be explained by reduction of macular edema. The results suggests that bevacizumab is a potent antiangiogenic that may reduce the progression of SNPDR and PDR.
This PDF is available to Subscribers Only